Netris Pharma News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

The antibody is believed to block a protein in cancer cells and could make chemotherapy more effective

Laboratory findings have set the stage for a clinical trial investigating a drug for pancreatic cancer that has spread to the liver.

Pancreatic cancer is tricky to manage because it spreads easily and early, and the tumors have a unique biological makeup.

<p>A new scientific finding at the University of Rochester is the foundation for the first clinical trial in the U.S. to study an experimental drug's ability to fight pancreatic cancer with metastasis to the liver. The trial is expected to launch early in 2024 at UR's Wilmot Cancer Institute. </p> <p> </p> <p> </p>

Get latest articles and stories on Science at LatestLY. Pancreatic cancer is difficult to treat because it spreads quickly and has a distinct biochemical makeup. However, researchers achieved a significant advance by discovering the genetic changes that occur during tumour migration -- and they also discovered a medication that may block the process. Science News | Pancreatic Cancer Discovery Opens Door for New Clinical Trial: Research.

Blocking epithelial–mesenchymal transition (EMT) in tumours reduces their ability to give rise to metastases and sensitises the tumour cells to chemotherapy.

Company’s candidate NP137 combined with mFOLFIRINOX will be researched during vital trials - News - PharmaTimes

Trial will evaluate efficacy of anti-netrin-1 antibody candidate NP137 in combination with Atezo-bev - News - PharmaTimes

The French delegation at BIO on June 13-16 has a compelling story to tell about biopharma and medtech growth and investment in France and the U.S. Here's a preview of some of the companies that will be at the convention, events they will host and why you should check them out.